REG - AstraZeneca PLC - Filing of Form 20-F with SEC

AstraZenecaAnnouncement

19/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250219:nRSS5988Xa&default-theme=true

RNS Number : 5988X  AstraZeneca PLC  19 February 2025

19 February 2025

 

 

Filing of Annual Report on Form 20-F with the US Securities and Exchange
Commission

 

AstraZeneca PLC (the Company) announced today that, on 18 February 2025, it
filed its 2024 Annual Report on Form 20-F with the US Securities and Exchange
Commission (SEC). The document is available for viewing on the SEC website
at www.sec.gov (http://www.sec.gov) and also on the Company's website at
www.astrazeneca.com (http://www.astrazeneca.com) . The Company will send any
holder of the Company's securities, upon request, a hard copy of the Company's
complete audited financial statements free of charge. Requests may be made by
writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue,
Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients
worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and
follow the Company on social media @AstraZeneca
(http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSSFMEFAEISEEE